Journal
JOURNAL OF THE AMERICAN HEART ASSOCIATION
Volume 11, Issue 16, Pages -Publisher
WILEY
DOI: 10.1161/JAHA.122.025369
Keywords
athletes; return-to-play; SARS-CoV-2; troponin
Categories
Funding
- American Medical Society for Sports Medicine (AMSSM) Foundation
- AMSSM Collaborative Research Network
- University of British Columbia Clinician Investigator Program
Ask authors/readers for more resources
Abnormal cTn appears to have limited diagnostic utility in return to play cardiac screening following SARS-CoV-2 infection.
BACKGROUND: Initial protocols for return to play cardiac testing in young competitive athletes following SARS-CoV-2 infection recommended cardiac troponin (cTn) to screen for cardiac involvement. This study aimed to define the diagnostic yield of cTn in athletes undergoing cardiovascular testing following SARS-CoV-2 infection. METHODS AND RESULTS: This prospective, observational cohort study from ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) included collegiate athletes who underwent cTn testing as a component of return to play protocols following SARS-CoV-2 infection. The cTn values were stratified as undetectable, detectable but within normal limits, and abnormal (>99% percentile). The presence of probable or definite SARS-CoV-2 myocardial involvement was compared between those with normal versus abnormal cTn levels. A total of 3184/3685 (86%) athletes in the ORCCA database met the inclusion criteria for this study (age 20 +/- 1 years, 32% female athletes, 28% Black race). The median time from SARS-CoV-2 diagnosis to cTn testing was 13 days (interquartile range, 11, 18 days). The cTn levels were undetectable in 2942 athletes (92%), detectable but within normal limits in 210 athletes (7%), and abnormal in 32 athletes (1%). Of the 32 athletes with abnormal cTn testing, 19/32 (59%) underwent cardiac magnetic resonance imaging, 30/32 (94%) underwent transthoracic echocardiography, and 1/32 (3%) did not have cardiac imaging. One athlete with abnormal troponin met the criteria for definite or probable SARS-CoV-2 myocardial involvement. In the total cohort, 21/3184 (0.7%) had SARS-CoV-2 myocardial involvement, among whom 20/21 (95%) had normal troponin testing. CONCLUSIONS: Abnormal cTn during routine return to play cardiac screening among competitive athletes following SARSCoV-2 infection appears to have limited diagnostic utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available